Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months, ≤0.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP / Baccarani, Michele; Abruzzese, Elisabetta; Accurso, Vincenzo; Albano, Francesco; Annunziata, Mario; Barulli, Sara; Beltrami, Germana; Bergamaschi, Micaela; Binotto, Gianni; Bocchia, Monica; Caocci, Giovanni; Capodanno, Isabella; Cavazzini, Francesco; Cedrone, Michele; Cerrano, Marco; Crugnola, Monica; D'Adda, Mariella; Elena, Chiara; Fava, Carmen; Fazi, Paola; Fozza, Claudio; Galimberti, Sara; Giai, Valentina; Gozzini, Antonella; Gugliotta, Gabriele; Iurlo, Alessandra; La Barba, Gaetano; Levato, Luciano; Lucchesi, Alessandro; Luciano, Luigia; Lunghi, Francesca; Lunghi, Monia; Malagola, Michele; Marasca, Roberto; Martino, Bruno; Melpignano, Angela; Miggiano, Maria Cristina; Montefusco, Enrico; Musolino, Caterina; Palmieri, Fausto; Pregno, Patrizia; Rapezzi, Davide; Rege-Cambrin, Giovanna; Rupoli, Serena; Salvucci, Marzia; Sancetta, Rosaria; Sica, Simona; Spadano, Raffaele; Stagno, Fabio; Tiribelli, Mario; Tomassetti, Simona; Trabacchi, Elena; Bonifacio, Massimiliano; Breccia, Massimo; Castagnetti, Fausto; Pane, Fabrizio; Russo, Domenico; Saglio, Giuseppe; Soverini, Simona; Vigneri, Paolo; Rosti, Gianantonio. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:24(2019), pp. 4280-4290. [10.1182/bloodadvances.2019000865]

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Marasca, Roberto;
2019

Abstract

Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months, ≤0.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.
2019
3
24
4280
4290
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP / Baccarani, Michele; Abruzzese, Elisabetta; Accurso, Vincenzo; Albano, Francesco; Annunziata, Mario; Barulli, Sara; Beltrami, Germana; Bergamaschi, Micaela; Binotto, Gianni; Bocchia, Monica; Caocci, Giovanni; Capodanno, Isabella; Cavazzini, Francesco; Cedrone, Michele; Cerrano, Marco; Crugnola, Monica; D'Adda, Mariella; Elena, Chiara; Fava, Carmen; Fazi, Paola; Fozza, Claudio; Galimberti, Sara; Giai, Valentina; Gozzini, Antonella; Gugliotta, Gabriele; Iurlo, Alessandra; La Barba, Gaetano; Levato, Luciano; Lucchesi, Alessandro; Luciano, Luigia; Lunghi, Francesca; Lunghi, Monia; Malagola, Michele; Marasca, Roberto; Martino, Bruno; Melpignano, Angela; Miggiano, Maria Cristina; Montefusco, Enrico; Musolino, Caterina; Palmieri, Fausto; Pregno, Patrizia; Rapezzi, Davide; Rege-Cambrin, Giovanna; Rupoli, Serena; Salvucci, Marzia; Sancetta, Rosaria; Sica, Simona; Spadano, Raffaele; Stagno, Fabio; Tiribelli, Mario; Tomassetti, Simona; Trabacchi, Elena; Bonifacio, Massimiliano; Breccia, Massimo; Castagnetti, Fausto; Pane, Fabrizio; Russo, Domenico; Saglio, Giuseppe; Soverini, Simona; Vigneri, Paolo; Rosti, Gianantonio. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:24(2019), pp. 4280-4290. [10.1182/bloodadvances.2019000865]
Baccarani, Michele; Abruzzese, Elisabetta; Accurso, Vincenzo; Albano, Francesco; Annunziata, Mario; Barulli, Sara; Beltrami, Germana; Bergamaschi, Micaela; Binotto, Gianni; Bocchia, Monica; Caocci, Giovanni; Capodanno, Isabella; Cavazzini, Francesco; Cedrone, Michele; Cerrano, Marco; Crugnola, Monica; D'Adda, Mariella; Elena, Chiara; Fava, Carmen; Fazi, Paola; Fozza, Claudio; Galimberti, Sara; Giai, Valentina; Gozzini, Antonella; Gugliotta, Gabriele; Iurlo, Alessandra; La Barba, Gaetano; Levato, Luciano; Lucchesi, Alessandro; Luciano, Luigia; Lunghi, Francesca; Lunghi, Monia; Malagola, Michele; Marasca, Roberto; Martino, Bruno; Melpignano, Angela; Miggiano, Maria Cristina; Montefusco, Enrico; Musolino, Caterina; Palmieri, Fausto; Pregno, Patrizia; Rapezzi, Davide; Rege-Cambrin, Giovanna; Rupoli, Serena; Salvucci, Marzia; Sancetta, Rosaria; Sica, Simona; Spadano, Raffaele; Stagno, Fabio; Tiribelli, Mario; Tomassetti, Simona; Trabacchi, Elena; Bonifacio, Massimiliano; Breccia, Massimo; Castagnetti, Fausto; Pane, Fabrizio; Russo, Domenico; Saglio, Giuseppe; Soverini, Simona; Vigneri, Paolo; Rosti, Gianantonio
File in questo prodotto:
File Dimensione Formato  
Baccarani Blood Adv 2019.pdf

Open access

Descrizione: Lavoro in extenso
Tipologia: Versione pubblicata dall'editore
Dimensione 837.62 kB
Formato Adobe PDF
837.62 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1187015
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 60
social impact